Cerebrolysin
Few neurological preparations have such an old and such a debated clinical corpus. Cerebrolysin intrigues as much through its published results as through the complexity of its composition.
- Research Use Only
- Molecule under study
- Living document
View the corresponding reference in the shop
- Current research state
- Authorized in several countries through national procedures; not approved by the FDA in the United States. Heterogeneous clinical data.
- Current clinical phase
- Multiple clinical trials — meta-analyses being updated
- Last update
- 20 July 2026 · Reference fact sheet v1.0
- Living document
- Updated regularly as research progresses.
What is Cerebrolysin?
Cerebrolysin is a complex biotechnological preparation obtained from porcine brain tissue through standardized enzymatic hydrolysis.
The final product contains free amino acids and a mixture of low-molecular-weight peptides (typically below 10 kDa), without the original large proteins.
It is developed by Ever Neuro Pharma (Austria) and used clinically in several countries in Central and Eastern Europe, Asia, and Latin America, mainly for neurological indications.
Names you may come across
This molecule is mainly designated under the following names in the literature.
The product's official name, as used by the manufacturer and in scientific publications.
The general description of the type of preparation.
Understanding it simply
A few simple points are helpful for understanding Cerebrolysin.
A mixture, not a single molecule
Unlike most of the molecules described in the Academy, Cerebrolysin is not a single molecule: it is a standardized mixture of peptides and amino acids.
A neurotrophic rationale
Studies suggest a “neurotrophic” action, meaning support for nerve cell survival and function, although the precise mechanism has not been fully elucidated.
A long clinical history
It has been used clinically for several decades in several countries. This long history has generated both actual data and extensive scientific debate about the magnitude of the benefit.
What research shows today
Science advances step by step. We clearly distinguish what is firmly established from what remains under study.
- Composition (low-molecular-weight peptide fragments and free amino acids) documented by the manufacturer. — established
- Randomized controlled trials published in ischemic stroke, vascular dementia, Alzheimer's disease, and traumatic brain injury. — established
- Meta-analyses and Cochrane reviews available. — established
- Overall clinical benefit considered uncertain by several systematic reviews (heterogeneous data across indications). — ongoing
- Not approved by the FDA in the United States. — ongoing
Clinical use in several countries, published randomized trials, and available meta-analyses, but Cochrane reviews conclude that the data remain heterogeneous and the overall clinical benefit is uncertain.
What the research shows
- The composition of Cerebrolysin and its manufacturing process are documented by the manufacturer and in the scientific literature.
- Numerous randomized clinical trials have been published in ischemic stroke, vascular dementia, Alzheimer's disease, and traumatic brain injury.
- Several meta-analyses have been published, notably by the Cochrane group.
What still remains to be studied
- Cochrane reviews conclude that the data remain heterogeneous, with uncertainty about the true magnitude of the clinical benefit.
- The methodological quality of studies varies considerably across indications and centers.
- Not approved by the FDA in the United States; assessment by some Western agencies remains more cautious than in countries where the product is used clinically.
What we know today
Not all information carries the same weight of evidence. We therefore present it across three clearly distinct levels, from the most solid to the most indicative.
What scientific publications show
Scientific evidence- Some trials report functional improvement after ischemic stroke, particularly when treatment is initiated early — but the overall effect remains debated at the meta-analysis level.
- Published trials in Alzheimer's disease and vascular dementia show variable results depending on the protocols and populations.
- Preclinical studies suggest neurotrophic and neuroprotective effects in animal models.
What some professionals report
Documented- Clinicians using Cerebrolysin emphasize the importance of administration in a medical setting (most often by intravenous infusion), with monitoring.
- Systematic reviews call for further trials of high methodological quality to reach clearer conclusions.
What the community reports
Field observations- Reported experiences vary from person to person and cannot replace clinical data.
- The community regularly highlights the product's distinctive feature: a peptide mixture, rather than a single molecule.
Observations reported by the community do not constitute scientific evidence. For Cerebrolysin, even more than for other molecules, clinical assessment rests on randomized trials and their meta-analyses, with the limitations they acknowledge.
How does Cerebrolysin work?
Cerebrolysin does not act through a single receptor: it is described as having a “pleiotropic” action, meaning multiple effects on several systems at once.
- Neurotrophic effects
- Investigated support for neuronal survival, compared in some studies with the action of endogenous neurotrophic factors.
- Neuroprotection
- Observed reduction in certain markers of neuronal injury in preclinical models of ischemia.
- Inflammatory modulation
- Effects on neuroinflammatory markers described in several preclinical studies.
- Synaptic plasticity
- Potential support for synaptic plasticity suggested in the preclinical literature.
- 1Neurons · Cerveau
Main target described: support for neuronal survival under conditions of injury or distress (ischemia, neurodegeneration).
The multi-target nature of Cerebrolysin is both its distinctive feature and one reason why its precise mechanism remains difficult to demonstrate.
Clinical trials timeline
A molecule under study progresses step by step. Here, simply, is where the research currently stands.
- Development· 1970sCompleted
Development of the preparation
Cerebrolysin is developed in Austria from porcine brain tissue using a standardized enzymatic hydrolysis process.
- Clinical· 1980s-1990sCompleted
Successive approvals
The product is approved as a medicine in several countries in Central and Eastern Europe, Asia, and Latin America.
- Clinical· 2000s-2010sCompleted
Trials in stroke and dementia
Numerous randomized clinical trials are published in ischemic stroke (notably the CARS and CASTA trials) and dementia.
- Reassessment· 2010s-2020sCompleted
Meta-analyses and Cochrane reviews
Several meta-analyses, including Cochrane reviews, conclude that the data remain heterogeneous across indications, calling for further trials of high methodological quality.
- Ongoing· CurrentlyOngoing
Continued use and investigation
Cerebrolysin remains in clinical use in countries where it is approved and continues to be the subject of trials and updated meta-analyses.
Available analyses
No analytical document has been published for this molecule to date.
Open the analysis libraryFrequently asked questions
Is Cerebrolysin an approved medicine?
It is authorized as a medicine in several countries through national procedures, but not by the FDA in the United States. PHL presents it here for educational and reference purposes (Research Use Only).
Why is it so controversial?
Established: numerous clinical trials have been published. Requires further study: Cochrane reviews conclude that the data remain heterogeneous across indications, with uncertainty about the true magnitude of the benefit. This contrast explains the scientific debate.
Is it a single molecule?
No. It is a complex preparation: a standardized mixture of low-molecular-weight peptides and free amino acids, obtained from porcine brain tissue through enzymatic hydrolysis.
Can it be used after a stroke?
In countries where it is approved, it may be prescribed by a physician for certain neurological indications. This type of use is strictly the responsibility of a qualified healthcare professional — PHL makes no medical recommendations.
How is it administered in studies?
Established: in the vast majority of clinical studies, it is administered intravenously or intramuscularly in a medical setting.
What side effects have been described?
Established: trials mainly describe infrequent effects (dizziness, injection-site reactions). However, the 2020 Cochrane review on acute ischemic stroke found no benefit on mortality and reported a possible increase in non-fatal serious adverse events (moderate certainty). To be studied: long-term tolerability and use outside authorized indications.
Scientific publications
A selection of trials, meta-analyses, and reference reviews on Cerebrolysin. All are genuine and verifiable. An evolving bibliography.
Glossary
- Peptide
- A short chain of amino acids.
- Enzymatic hydrolysis
- A chemical process using enzymes to break proteins down into smaller fragments (peptides and amino acids).
- Neurotrophic
- Describes something that supports nerve cell survival and function.
- Neuroprotection
- The set of mechanisms that protect neurons against stress (for example, ischemic stress).
- Ischaemic stroke
- A stroke caused by the blockage of a blood vessel in the brain.
- Vascular dementia
- A form of dementia related to vascular damage in the brain (often after repeated strokes).
- Meta-analysis
- A study that combines the results of several trials to reach an overall conclusion.
- Cochrane
- An internationally recognized organization for the critical appraisal of medical evidence.
Continue your discovery
Read next
Sheets that are thematically close. These links serve reading and discovery — they suggest no combined use.
Reference fact sheet — version 1.0, updated on 20 July 2026. The full regulatory and scientific framework is gathered in the “Important information” box at the top of the fact sheet.
Explore the fundamentals related to this goal
This general content is independent of the molecule and is neither a use strategy nor a protocol.